Reuters logo
BRIEF-‍Aquinox Statement On Fda Advisory Committee Meeting To Discuss Interstitial Cystitis/Bladder Pain Syndrome​
December 8, 2017 / 4:01 AM / 5 days ago

BRIEF-‍Aquinox Statement On Fda Advisory Committee Meeting To Discuss Interstitial Cystitis/Bladder Pain Syndrome​

Aquinox Pharmaceuticals Inc:

* ‍AQUINOX STATEMENT ON FDA ADVISORY COMMITTEE MEETING TO DISCUSS INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME​

* AQUINOX - FDA PANEL VOTED 15 TO 0 THAT PATIENTS WITH INTERSTITIAL CYSTITIS, PATIENTS WITH BLADDER PAIN SYNDROME SHOULD BE COMBINED IN CLINICAL TRIALS​

* - FDA ‍COMMITTEE‘S VOTE IS ALIGNED WITH APPROACH CO HAVE TAKEN IN AQUINOX‘S CLINICAL DEVELOPMENT PROGRAM FOR ROSIPTOR​

* ‍LOOK FORWARD TO ADDITIONAL INTERACTION WITH AGENCY BASED ON TODAY‘S DISCUSSION​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below